ERBB2 and neoplasm: Compared with the bispecific counterparts, the structurally optimized tsAb demonstrated prolonged half-life and enhanced antitumor efficacy against Her2- and/or VEGFR2-expressing tumors, especially in the Herceptin- and Cyramza-resistant tumor models [187].